Latest & greatest articles for prednisolone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisolone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisolone

1. HYDROCORTANCYL (prednisolone), glucocorticoid

HYDROCORTANCYL (prednisolone), glucocorticoid Haute Autorité de Santé - HYDROCORTANCYL (prednisolone), glucocorticoïde Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments HYDROCORTANCYL (prednisolone), glucocorticoïde Substance active (DCI) prednisolone RHUMATOLOGIE - Mise au point Nature de la demande Réévaluation SMR Avis de la CT du 09

Haute Autorite de sante2018

2. Prednisolone

Prednisolone Top results for prednisolone - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prednisolone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma

A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma 29331473 2018 03 09 1931-3543 153 3 2018 Mar Chest Chest A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. 656-664 S0012-3692(18)30077-1 10.1016/j.chest.2018.01.005 Whether itraconazole monotherapy is effective in the acute stage of allergic bronchopulmonary aspergillosis (ABPA) remains unknown (...) . The goal of this study was to compare the efficacy and safety of itraconazole and prednisolone monotherapy in ABPA. Treatment-naive subjects with ABPA complicating asthma (January 2012 to December 2013) were randomized to receive either oral itraconazole or prednisolone for 4 months. The study was not blinded. The primary outcomes were proportion of subjects exhibiting a composite response after 6 weeks, percent decline in IgE after treatment, and numbers of subjects experiencing exacerbation

EvidenceUpdates2018

4. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone European Medicines Agency - News and Events - Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Search for medicines Main navigation News and press releases Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Ongoing (...) clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate

European Medicines Agency - EPARs2018

5. Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures

Radium-223 dichloride (Xofigo): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures - GOV.UK GOV.UK uses cookies to make the site simpler. Search Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone (...) and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures From: Published: 14 December 2017 Therapeutic area: and A European review has begun into the safety of radium-223 dichloride following an observed increase in the incidence of deaths and fractures in patients with chemotherapy-naive metastatic castration-resistant prostate cancer receiving radium-223 dichloride in combination with abiraterone acetate (Zytiga) and prednisone/prednisolone as part of a clinical

MHRA Drug Safety Update2017

6. Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial.

Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection: A Randomized Clinical Trial. Importance: Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. Objective: To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma. Design (...) , Setting, and Participants: Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices in England among 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disease or use of asthma medication in the past 5 years. Interventions: Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once daily for 5 days. Main

JAMA2017

7. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.

Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Importance: Oral glucocorticoid treatment increases fracture risk, and evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids. Objective: To investigate whether alendronate treatment in older patients using oral prednisolone is associated with decreased hip fracture risk and adverse effects. Design, Setting (...) , and Participants: Retrospective cohort study using a national database (N = 433 195) of patients aged 65 years or older undergoing a health evaluation (baseline) at Swedish health care facilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment (≥5 mg/d) were identified. Propensity score matching was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone with the same dose and treatment time criteria. Follow-up occurred

JAMA2017

8. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA 28043903 2017 01 03 2017 04 03 1528-0012 152 5 2017 Apr Gastroenterology Gastroenterology In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. 1068-1077.e4 S0016 (...) -5085(16)35533-0 10.1053/j.gastro.2016.12.019 Infections are common in patients with severe alcoholic hepatitis (SAH), but little information is available on how to predict their development or their effects on patients. Prednisolone is advocated for treatment of SAH, but can increase susceptibility to infection. We compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH. We analyzed

EvidenceUpdates2017

9. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids. METHODS: We did a pragmatic, multicentre, parallel-group (...) randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were

Lancet2017

10. A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL

A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids (...) -inferior to standard treatment with oral prednisolone for short-term blister control and considerably safer in the long term. {{author}} {{($index , , , , , , , , , , , & . Joanne R Chalmers, 1 Fenella Wojnarowska, 2 Gudula Kirtschig, 1 James Mason, 3 Margaret Childs, 4 Diane Whitham, 4 Karen Harman, 5 Anna Chapman, 6 Shernaz Walton, 7 Enno Schmidt, 8 Thomas R Godec, 9 Andrew J Nunn, 9 Hywel C Williams, 1 ,* 1 Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK 2 Nuffield

NIHR HTA programme2017

11. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial.

Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. 26903390 2016 04 05 2016 08 18 2016 04 05 1539-3704 164 7 2016 Apr 05 Annals of internal medicine Ann. Intern. Med. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. 464-71 10.7326/M14-2070 Two recent double-blind, randomized, controlled trials (RCTs) showed that oral steroids and nonsteroidal anti-inflammatory drugs have similar (...) analgesic effectiveness for management of gout, but the trials had small sample sizes and other methodological limitations. To compare the effectiveness and safety of oral prednisolone versus oral indomethacin in patients presenting to emergency departments (EDs) with acute gout. Multicenter, double-blind, randomized equivalence trial. Patients were randomly assigned (1:1 ratio) to receive either indomethacin or prednisolone. (ISRCTN registry number: ISRCTN45724113). Four EDs in Hong Kong. 416 patients

Annals of Internal Medicine2016

12. Pentoxifylline vs. Prednisolone: A Comparison of Efficacy in the Treatment of Severe Alcoholic Hepatitis in Adult Patients

Pentoxifylline vs. Prednisolone: A Comparison of Efficacy in the Treatment of Severe Alcoholic Hepatitis in Adult Patients "Pentoxifylline vs. Prednisolone: A Comparison of Efficacy in the Treat" by Ashley A. Hilliker < > > > > > Title Author Date of Award Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Professor Sommers Rights . Abstract Background: Alcoholic hepatitis is a chronic, inflammatory liver disease (...) that is on the rise in the United States. Traditionally, the progression of severe alcoholic hepatitis has been slowed with a 28-day course of prednisolone. However, since corticosteroids such as prednisolone have been associated with increased risk of infection and multiple unpleasant side effects, newer research is aimed at using pentoxifylline (PTX) as an alternative treatment. PTX has been shown to have a better safety profile than prednisolone, but its effectiveness in the treatment of severe alcoholic

Pacific University EBM Capstone Project2016

13. Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia

Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia 25614171 2015 06 01 2016 02 23 2016 11 25 1399-3003 45 6 2015 Jun The European respiratory journal Eur. Respir. J. Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. 1624-31 10.1183/09031936.00199614 In patients with chronic eosinophilic pneumonia (CEP), dramatic improvements are seen in response to corticosteroid therapy; however, relapse is common after (...) treatment has ceased. The optimal duration of corticosteroid therapy remains unclear. In a randomised, open-label, parallel group study, eligible patients with CEP received oral prednisolone for either 3 months (3-month group) or 6 months (6-month group), followed by 2 years observation. All patients were treated with an initial dose of prednisolone of 0.5 mg·kg(-1)·day(-1), which was then tapered and discontinued at either 3 or 6 months. The primary end-point was relapse during the follow-up period

EvidenceUpdates2015

14. Prednisolone or pentoxifylline for alcoholic hepatitis.

Prednisolone or pentoxifylline for alcoholic hepatitis. 25901427 2015 04 23 2015 04 30 2015 12 14 1533-4406 372 17 2015 Apr 23 The New England journal of medicine N. Engl. J. Med. Prednisolone or pentoxifylline for alcoholic hepatitis. 1619-28 10.1056/NEJMoa1412278 Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol use. The short-term mortality among patients with severe disease exceeds (...) 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists. We conducted a multicenter, double-blind, randomized trial with a 2-by-2 factorial design to evaluate the effect of treatment with prednisolone or pentoxifylline. The primary end point was mortality at 28 days. Secondary end points included death or liver transplantation at 90 days and at 1 year. Patients with a clinical diagnosis of alcoholic

NEJM2015

15. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations?

Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2015

16. Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran

Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran 25960848 2015 05 11 2015 05 11 2017 02 20 2008-2398 8 2 2015 Mar-Apr Iranian journal of cancer prevention Iran J Cancer Prev Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran. 94-9 Chronic lymphocytic leukemia (CLL) has been the most common type of leukemia in adults worldwide, and then more common (...) follow up. The mean age of patients was 61.57±8.88 years that 55.7% were males. Between the 70 patients, 40 patients (57.1%) have started treatment with chlorambucil and 30 patients (42.9%) with chlorambucil plus prednisolone. Among the forty patients that have treated with chlorambucil, overall response rate was 95% that 9 patients (22.5%) had complete response. Among the 30 patients that have treated with chlorambucil plus prednisolone, overall response rate was 96%, that 9 patients (30%) had

Iranian journal of cancer prevention2015 Full Text: Link to full Text with Trip Pro

17. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

18. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. BACKGROUND: Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis. METHODS: Using a 2-by-2 factorial design, we randomly assigned 1400 adults with definite or probable tuberculous pericarditis to either (...) prednisolone or placebo for 6 weeks and to either M. indicus pranii or placebo, administered in five injections over the course of 3 months. Two thirds of the participants had concomitant human immunodeficiency virus (HIV) infection. The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. RESULTS: There was no significant difference in the primary outcome between patients who received prednisolone and those who received placebo

NEJM2014

19. Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis.

Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis. 25178809 2014 09 18 2014 09 30 2017 03 01 1533-4406 371 12 2014 Sep 18 The New England journal of medicine N. Engl. J. Med. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. 1121-30 10.1056/NEJMoa1407380 Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy (...) and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis. Using a 2-by-2 factorial design, we randomly assigned 1400 adults with definite or probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. indicus pranii or placebo, administered in five injections over the course of 3 months. Two thirds of the participants had concomitant human immunodeficiency virus (HIV) infection. The primary efficacy outcome was a composite of death, cardiac

NEJM2014

20. Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department

Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Article Text

Evidence-Based Medicine (Requires free registration)2014